Trevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading Volume – What’s Next?

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) saw unusually-high trading volume on Friday . Approximately 1,271,739 shares were traded during mid-day trading, a decline of 6% from the previous session’s volume of 1,349,267 shares.The stock last traded at $15.1110 and had previously closed at $14.54.

More Trevi Therapeutics News

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Pricing of an underwritten offering will provide ~ $150M in gross proceeds to fund Haduvio development and extend runway — this reduces near-term cash risk for clinical programs. Read More.
• Positive Sentiment: D. Boral Capital reiterated a “Buy” and set a $19 price target (about mid‑teens upside from the current level), which supports positive analyst sentiment and can attract buyers. Read More.
• Neutral Sentiment: The offering was priced at $13.00 per share for 11.6M shares, with a 30‑day option for an additional 1.74M shares; expected close is on or about April 20, subject to customary conditions. This is procedural but important to completion. Read More.
• Neutral Sentiment: Underwriters include Morgan Stanley, Leerink, Cantor and Stifel — participation by major banks can help execution and distribution of the deal. Read More.
• Negative Sentiment: All shares in the offering are being sold by Trevi, which dilutes existing shareholders and may pressure near-term per‑share metrics. Expect increased share count and potential short‑term selling pressure once shares are issued. Read More.
• Negative Sentiment: Market reaction was immediate: the announcement triggered a sharp intraday selloff in some reports, signaling investor sensitivity to dilution and near‑term capital raises. Expect elevated volatility while the deal closes. Read More.

Analyst Ratings Changes

TRVI has been the topic of several research reports. JonesTrading lowered their price objective on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, March 19th. Oppenheimer reaffirmed an “outperform” rating on shares of Trevi Therapeutics in a research report on Monday, March 9th. Needham & Company LLC lifted their price objective on shares of Trevi Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th. D. Boral Capital reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Trevi Therapeutics in a research report on Friday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $21.60.

Trevi Therapeutics Price Performance

The stock has a market cap of $1.96 billion, a PE ratio of -47.59 and a beta of 0.99. The firm’s 50 day moving average price is $11.83 and its two-hundred day moving average price is $11.57.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.04. Analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds have recently bought and sold shares of the company. Flputnam Investment Management Co. lifted its holdings in shares of Trevi Therapeutics by 1,105.4% in the 3rd quarter. Flputnam Investment Management Co. now owns 1,048,102 shares of the company’s stock worth $9,590,000 after acquiring an additional 961,150 shares during the last quarter. Peregrine Capital Management LLC bought a new stake in shares of Trevi Therapeutics in the 3rd quarter worth approximately $5,677,000. Pivotal bioVenture Partners Investment Advisor LLC lifted its holdings in shares of Trevi Therapeutics by 9.7% in the 3rd quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 1,256,782 shares of the company’s stock worth $11,500,000 after acquiring an additional 110,672 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Trevi Therapeutics by 93.0% in the 4th quarter. SG Americas Securities LLC now owns 124,562 shares of the company’s stock worth $1,560,000 after acquiring an additional 60,017 shares during the last quarter. Finally, Nan Fung Trinity HK Ltd. bought a new stake in shares of Trevi Therapeutics in the 3rd quarter worth approximately $820,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.